Zunica Elizabeth R M, Heintz Elizabeth C, Axelrod Christopher L, Kirwan John P
Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808, USA.
Cancers (Basel). 2022 Aug 22;14(16):4051. doi: 10.3390/cancers14164051.
Hepatocellular carcinoma (HCC) is the most frequent primary hepatic malignancy and a leading cause of cancer-related death globally. HCC is associated with an indolent clinical presentation, resulting in frequent advanced stage diagnoses where surgical resection or transplant therapies are not an option and medical therapies are largely ineffective at improving survival. As such, there is a critical need to identify and enhance primary prevention strategies to mitigate HCC-related morbidity and mortality. Obesity is an independent risk factor for the onset and progression of HCC. Furthermore, obesity is a leading cause of nonalcoholic steatohepatitis (NASH), the fasting growing etiological factor of HCC. Herein, we review evolving clinical and mechanistic associations between obesity and hepatocarcinogenesis with an emphasis on the therapeutic efficacy of prevailing lifestyle/behavioral, medical, and surgical treatment strategies for weight reduction and NASH reversal.
肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤,也是全球癌症相关死亡的主要原因。HCC的临床表现较为隐匿,导致晚期诊断频繁,此时手术切除或移植治疗并非选择,而药物治疗在提高生存率方面大多无效。因此,迫切需要确定并加强一级预防策略,以减轻与HCC相关的发病率和死亡率。肥胖是HCC发病和进展的独立危险因素。此外,肥胖是非酒精性脂肪性肝炎(NASH)的主要原因,而NASH是HCC发病率增长最快的病因。在此,我们综述肥胖与肝癌发生之间不断演变的临床和机制关联,重点关注当前生活方式/行为、药物和手术治疗策略在减轻体重和逆转NASH方面的治疗效果。